Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 13/20 | 0.43 |
| ▸ | F3 | P13726 | 6/20 | 0.40 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790581 | 1.00 | F7 (0.43) | F7F3F2ELANERAB9A | |
| SCHEMBL6794756 | 0.93 | F7 (0.42) | F7F3F2ELANERAB9A | |
| SCHEMBL6794761 | 0.93 | F7 (0.42) | F7F3F2ELANERAB9A | |
| SCHEMBL8363673 | 0.82 | F7 (0.65) | F7F3F2 | |
| SCHEMBL8363354 | 0.80 | F7 (0.55) | F7F3F2 | |
| SCHEMBL8363431 | 0.77 | F7 (0.72) | F7F3F2 | |
| SCHEMBL8363182 | 0.77 | F7 (0.66) | F7F3F2 | |
| SCHEMBL8363196 | 0.77 | F7 (0.52) | F7F3F2 | |
| SCHEMBL6792873 | 0.76 | F7 (0.47) | F7F3F2 | |
| SCHEMBL6792879 | 0.76 | F7 (0.47) | F7F3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | F7 20/4885F3 16/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.